Galileo Resources Plc (GLR) announced that initial surface work has discovered a porphyry mineralised system within the Company’s Ferber licence. Galileo is working on the Ferber Licence alongside Bronco Creek Exploration Inc
Galileo Resources Plc (GLR) announced that initial surface work has discovered a porphyry mineralised system within the Company’s Ferber licence. Galileo is working on the Ferber Licence alongside Bronco Creek Exploration Inc
(Alliance News) – Stocks in London are set to open marginally higher on Thursday as investors monitored developments around the Strait of Hormuz while assessing another busy slate of corporate earnings.
Solvonis Therapeutics (LON: SVNS) shares surged 13% in early trading after the company announced positive preclinical pharmacokinetic data for its lead Alcohol Use Disorder treatment candidate, SVN-002, marking an important
The Telegraph: Sir Keir Starmer has resigned this morning, paving the way for Andy Burnham to become Britain’s seventh prime minister in a decade. Allies of Sir Keir expected him
Halfords Group plc (HFD), the UK’s leading provider of motoring and cycling products and services, is pleased to provide a strong trading update ahead of its FY26 results. Group like-for-like (“LfL”)
Rift Helium (RIFT) admitted to AIM on 22 Apr 2026 after raising £8.1m from a placing of 80.855m new shares at 10p, leaving 134,142,041 shares outstanding and a market capitalisation of
(Alliance News) – Keir Starmer has welcomed the ceasefire agreed between the US and Iran overnight and said it was an opportunity to secure a long-term solution for shipping through the
Atlas Metals (AMG), the natural resources and energy company, provided an update on the Company’s proposed acquisition of Universal Pozzolanic Silica Alumina Ltd. Further to the Company’s announcement on 28 November
Solvonis Therapeutics plc (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, announced that its novel AI-discovered compound, SVN-015, targeting methamphetamine and cocaine use disorders,
Solvonis’ Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction
Solvonis Therapeutics (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (“CNS”) disorders, announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.
The FTSE 100 closed firmly lower on Friday, marking one of its steepest one-day declines in a month as renewed US–China trade tensions rattled global markets.